Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Launches Inquiry Into Its Clinical Trials Problems After Pharma Outcry

Ex-Health Minister To Report Back In Spring

Executive Summary

Stung by criticism from the AstraZeneca and GSK CEOs, the UK government has launched an independent review into commercial clinical trials in the hopes of reversing a steep decline.

You may also be interested in...



UK To Combat Clinical Trial Issues With Upstream Support For Sponsors & International Collaboration

The UK medicines regulator is mulling the possibility of drawing on its existing international regulatory partnerships, such as the ACCESS Consortium, to tackle challenges in its clinical trials sector, and says sponsors can expect greater support early in the trial process.

UK Aims To Quadruple Patient Recruitment To Industry Clinical Trials By 2027

The UK government has set aside dedicated funds to deliver ambitious changes that would make it quicker and easier for companies to trial more of their products in the National Health Service. 

UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU

The UK has finalized plans for delivering what it believes will be a stable and streamlined clinical trials framework following its departure from the EU. Transparency, patient involvement and diversity are high on the agenda.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel